Malignant neoplasm of dome of bladder
ICD-10 C67.1 is a billable code used to indicate a diagnosis of malignant neoplasm of dome of bladder.
C67.1 refers to a malignant neoplasm located at the dome of the bladder, which is the uppermost part of the bladder. This type of cancer is classified under urinary tract malignancies and can present with various symptoms, including hematuria (blood in urine), dysuria (painful urination), and urinary frequency. The diagnosis is typically confirmed through imaging studies such as CT scans or MRIs, followed by cystoscopy and biopsy. Staging of bladder cancer is crucial for determining the extent of the disease and guiding treatment options. The American Joint Committee on Cancer (AJCC) staging system is commonly used, which includes stages from 0 (non-invasive) to IV (metastatic disease). Surgical management often involves transurethral resection of the bladder tumor (TURBT) for early-stage cancers, while more advanced cases may require partial or radical cystectomy. Adjuvant therapies, including chemotherapy and immunotherapy, may also be indicated based on the tumor's characteristics and staging.
Detailed pathology reports, imaging studies, and surgical notes are essential.
Diagnosis and management of bladder tumors, staging evaluations, and surgical interventions.
Ensure accurate coding of tumor size, grade, and stage to reflect treatment decisions.
Comprehensive treatment plans, chemotherapy regimens, and follow-up care notes.
Management of advanced bladder cancer, including chemotherapy and immunotherapy.
Documenting response to treatment and any complications that arise during therapy.
Used for diagnosis and staging of bladder tumors.
Document findings from cystoscopy and biopsy results.
Urologists must ensure accurate reporting of tumor characteristics.
Performed for localized malignant tumors.
Document the extent of resection and pathology findings.
Urologists must provide detailed operative notes.
Common symptoms include hematuria, dysuria, urinary frequency, and pelvic pain. Patients may also experience weight loss and fatigue as the disease progresses.
Staging is determined through imaging studies, cystoscopy, and biopsy results, following the AJCC staging system which assesses tumor size, lymph node involvement, and metastasis.
